NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer

Podobne zapisy

• Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
  od: Flocke, Lea S., i wsp.
  Wydane: (2016)
• The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
  od: Heffeter, Petra, i wsp.
  Wydane: (2013)
• Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse
  od: Blazevic, Amir, i wsp.
  Wydane: (2017)
• Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
  od: Heffeter, Petra, i wsp.
  Wydane: (2010)
• Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds
  od: Kowol, Christian R., i wsp.
  Wydane: (2011)